TAK Fair Value Estimate
$44.87169.0% undervalued
Blended fair value estimate based on DCF, Graham Number, and earnings-based models.
Takeda Pharmaceutical Company
Exchange: NYSESector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic
Values in USD · ADR · Reports in JPY
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries.
Current Price
$16.68
+0.60%GoodMoat Value
$44.87
169.0% undervaluedProfile
Valuation (TTM)
Market Cap$52.11B
P/E73.27
EV—
P/B1.12
Shares Out3.12B
P/Sales1.75
Revenue$29.80B
EV/EBITDA9.47
Takeda Pharmaceutical Company (TAK) Valuation
TAK Valuation Metrics
FCF$5.44B
FCF Growth Rate0.92%
EPS Growth (CAGR)19.61%
WACC10.00%
Fair Value Models
Graham Number, PEG-based, and Earnings-based models
View Fair Value →TAK Valuation & Fair Value Analysis
Takeda Pharmaceutical Company (TAK) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.
The GoodMoat Fair Value target for Takeda Pharmaceutical Company is $44.87. The current stock price is $16.68, suggesting the stock is 169.0% undervalued.
The price-to-earnings (P/E) ratio is 73.27. Price-to-book ratio is 1.12. Price-to-sales ratio is 1.75. Enterprise value to EBITDA is 9.47. PEG ratio is 0.21.
GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Takeda Pharmaceutical Company's intrinsic value.